Alpha 2.0
Login Register
» Authors » Paul C Hendrie

Paul C Hendrie

Explore the profile of Paul C Hendrie including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 825
Followers 0
Related Specialties
Hematology
Oncology
Pharmacology
Top 10 Co-Authors
Elihu H Estey
Roland B Walter
Pamela S Becker
Mary-Elizabeth M Percival
Megan Othus
Anna B Halpern
Bart L Scott
Ryan D Cassaday
Kelda M Gardner
Vivian G Oehler
Published In
Leuk Lymphoma
Haematologica
J Natl Compr Canc Netw
Leukemia
Mol Ther
Affiliations
Soon will be listed here.
Recent Articles
21.
Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia
Bezerra E, Othus M, Shawn C, Percival M, Gardner K, Walter R, et al.
Clin Lymphoma Myeloma Leuk . 2019 Oct; 19(12):e633-e635. PMID: 31648955
No abstract available.
22.
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
Halpern A, Howard N, Othus M, Hendrie P, Baclig N, Buckley S, et al.
Leukemia . 2019 Oct; 34(2):635-639. PMID: 31586148
No abstract available.
23.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Hirayama A, Gauthier J, Hay K, Voutsinas J, Wu Q, Gooley T, et al.
Blood . 2019 Feb; 133(17):1876-1887. PMID: 30782611
Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting...
24.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
Halpern A, Othus M, Huebner E, Scott B, Hendrie P, Percival M, et al.
Haematologica . 2018 Nov; 104(4):e143-e146. PMID: 30409798
No abstract available.
25.
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
Halpern A, Othus M, Huebner E, Scott B, Becker P, Percival M, et al.
Leukemia . 2018 May; 32(11):2352-2362. PMID: 29720734
Outcomes with "7 + 3" are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase...
26.
Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD
Cassaday R, Stevenson P, Wood B, Becker P, Hendrie P, Sandmaier B, et al.
Am J Hematol . 2018 Jan; 93(4):546-552. PMID: 29318644
HyperCVAD is a commonly-used regimen for adults with newly-diagnosed acute lymphoblastic leukemia (ALL). However, relatively little is known about the application of minimal residual disease (MRD) detection with this treatment....
27.
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
Walter R, Othus M, Orlowski K, McDaniel E, Scott B, Becker P, et al.
Haematologica . 2017 Dec; 103(3):e106-e109. PMID: 29242304
No abstract available.
28.
Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia
Chen X, Othus M, Wood B, Walter R, Percival M, Becker P, et al.
Leuk Lymphoma . 2017 Mar; 58(11):2717-2719. PMID: 28351184
No abstract available.
29.
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
Floeter A, Patel A, Tran M, Chamberlain M, Hendrie P, Gopal A, et al.
Clin Lymphoma Myeloma Leuk . 2017 Feb; 17(4):225-230. PMID: 28169156
Introduction: The purpose of our study was to identify the key risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of the combination chemotherapy regimen, DA-EPOCH...
30.
Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis
Vaughn J, Othus M, Powell M, Gardner K, Rizzuto D, Hendrie P, et al.
JAMA Oncol . 2015 Sep; 1(8):1120-7. PMID: 26355382
Importance: Adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) typically remain hospitalized after induction or salvage chemotherapy until blood cell count recovery, with resulting prolonged inpatient stays being...